• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Wnt5a通过调节前列腺癌细胞的干性和上皮-间质转化进程来促进血管生成拟态的形成。

Wnt5a promotes VM formation by modulating the stemness and EMT progression of prostate cancer cell.

作者信息

Liu Bide, Li Xun, Wang Shuheng, Jia Hongliang, Zhang Xiaoan, Dong Qiang, Li Jiuzhi

机构信息

Department of Urology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, 830001, China; Laboratory of Urology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, 830001, China.

Department of Urology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, 830001, China; Laboratory of Urology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, 830001, China.

出版信息

Transl Oncol. 2025 Jan;51:102155. doi: 10.1016/j.tranon.2024.102155. Epub 2024 Nov 1.

DOI:10.1016/j.tranon.2024.102155
PMID:39488007
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11565535/
Abstract

The incidence of prostate cancer (PCa) is increasing annually, making it the leading cause of tumor-related mortality in males. The available treatment options for metastatic PCa are limited. Vasculogenic mimicry (VM), an emerging phenomenon involving aggressive tumor cells, has a significant impact on patient survival. Misregulation of Wnt5a expression is commonly observed during cancer progression. However, there is a lack of comprehensive studies investigating the effects of Wnt5a on tumor VM formation. In this study, we demonstrate that alterations in wnt5a expression, either through gain or loss, have a significant influence on the formation of VM in tumor cells mediated by cell stemness and EMT progression. Further research has demonstrated that Wnt5a regulates the formation of VM through the PI3K/JNK signaling pathway. These experimental findings offer a novel avenue for the clinical management of prostate cancer.

摘要

前列腺癌(PCa)的发病率逐年上升,使其成为男性肿瘤相关死亡的主要原因。转移性PCa的现有治疗选择有限。血管生成拟态(VM)是一种涉及侵袭性肿瘤细胞的新现象,对患者生存有重大影响。在癌症进展过程中,通常会观察到Wnt5a表达失调。然而,缺乏全面研究来探究Wnt5a对肿瘤VM形成的影响。在本研究中,我们证明,通过增加或减少Wnt5a表达所引起的变化,对由细胞干性和上皮-间质转化(EMT)进程介导的肿瘤细胞中VM的形成有显著影响。进一步研究表明,Wnt5a通过PI3K/JNK信号通路调节VM的形成。这些实验结果为前列腺癌的临床治疗提供了一条新途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4df/11565535/8e0eb8ca78e2/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4df/11565535/a5f582b60417/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4df/11565535/84adf489983c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4df/11565535/2fcd515e6d0a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4df/11565535/7c3e28304a0d/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4df/11565535/7dc66400b90d/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4df/11565535/96082bcf0bfb/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4df/11565535/8e0eb8ca78e2/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4df/11565535/a5f582b60417/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4df/11565535/84adf489983c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4df/11565535/2fcd515e6d0a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4df/11565535/7c3e28304a0d/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4df/11565535/7dc66400b90d/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4df/11565535/96082bcf0bfb/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4df/11565535/8e0eb8ca78e2/gr6.jpg

相似文献

1
Wnt5a promotes VM formation by modulating the stemness and EMT progression of prostate cancer cell.Wnt5a通过调节前列腺癌细胞的干性和上皮-间质转化进程来促进血管生成拟态的形成。
Transl Oncol. 2025 Jan;51:102155. doi: 10.1016/j.tranon.2024.102155. Epub 2024 Nov 1.
2
Wnt5a promotes vasculogenic mimicry and epithelial-mesenchymal transition via protein kinase Cα in epithelial ovarian cancer.Wnt5a通过蛋白激酶Cα促进上皮性卵巢癌中的血管生成拟态和上皮-间质转化。
Oncol Rep. 2014 Aug;32(2):771-9. doi: 10.3892/or.2014.3229. Epub 2014 Jun 4.
3
Ginsenoside Rg3 suppresses vasculogenic mimicry by impairing DVL3-maintained stemness via PAAD cell-derived exosomal miR-204 in pancreatic adenocarcinoma.人参皂苷Rg3通过胰腺腺癌中PAAD细胞衍生的外泌体miR-204损害DVL3维持的干性来抑制血管生成拟态。
Phytomedicine. 2024 Apr;126:155402. doi: 10.1016/j.phymed.2024.155402. Epub 2024 Feb 1.
4
Dual VEGF/PDGF knockdown suppresses vasculogenic mimicry formation in choroidal melanoma cells via the Wnt5a/β-catenin/AKT signaling pathway.双重VEGF/PDGF基因敲低通过Wnt5a/β-连环蛋白/AKT信号通路抑制脉络膜黑色素瘤细胞中血管生成拟态的形成。
Acta Histochem. 2022 Jan;124(1):151842. doi: 10.1016/j.acthis.2021.151842. Epub 2022 Jan 5.
5
Tumor-expressed B7-H3 promotes vasculogenic mimicry formation rather than angiogenesis in non-small cell lung cancer.肿瘤表达的 B7-H3 促进非小细胞肺癌中的血管生成拟态形成而非血管生成。
J Cancer Res Clin Oncol. 2023 Sep;149(11):8729-8741. doi: 10.1007/s00432-023-04790-3. Epub 2023 May 2.
6
Galectin-1 Promotes Vasculogenic Mimicry in Gastric Cancer by Upregulating EMT Signaling.半乳糖凝集素-1通过上调上皮-间质转化信号促进胃癌中的血管生成拟态。
J Cancer. 2019 Oct 17;10(25):6286-6297. doi: 10.7150/jca.33765. eCollection 2019.
7
Notch1 promotes vasculogenic mimicry in hepatocellular carcinoma by inducing EMT signaling.Notch1通过诱导上皮-间质转化信号通路促进肝细胞癌中的血管生成拟态。
Oncotarget. 2017 Jan 10;8(2):2501-2513. doi: 10.18632/oncotarget.12388.
8
Inhibitory effect of melatonin on hypoxia-induced vasculogenic mimicry via suppressing epithelial-mesenchymal transition (EMT) in breast cancer stem cells.褪黑素通过抑制乳腺癌干细胞上皮-间充质转化(EMT)抑制低氧诱导的血管生成拟态。
Eur J Pharmacol. 2020 Aug 15;881:173282. doi: 10.1016/j.ejphar.2020.173282. Epub 2020 Jun 21.
9
Doublecortin-like kinase 1 promotes stem cell-like properties through the Hippo-YAP pathway in prostate cancer.双皮质素样激酶1通过Hippo-YAP信号通路促进前列腺癌的干细胞样特性。
Int J Med Sci. 2025 Jan 1;22(2):460-472. doi: 10.7150/ijms.99062. eCollection 2025.
10
Dickkopf-1-promoted vasculogenic mimicry in non-small cell lung cancer is associated with EMT and development of a cancer stem-like cell phenotype.Dickkopf-1促进非小细胞肺癌中的血管生成拟态,这与上皮-间质转化及癌症干细胞样细胞表型的形成有关。
J Cell Mol Med. 2016 Sep;20(9):1673-85. doi: 10.1111/jcmm.12862. Epub 2016 May 31.

引用本文的文献

1
Leptin-Upregulated Metastasis-Associated Protein 1 Promotes Vasculogenic Mimicry in Breast Cancer Cells.瘦素上调的转移相关蛋白1促进乳腺癌细胞的血管生成拟态
Int J Mol Sci. 2025 Jun 15;26(12):5726. doi: 10.3390/ijms26125726.

本文引用的文献

1
Therapeutic potential of vasculogenic mimicry in urological tumors.血管生成拟态在泌尿系统肿瘤中的治疗潜力
Front Oncol. 2023 Sep 21;13:1202656. doi: 10.3389/fonc.2023.1202656. eCollection 2023.
2
WNT5A: a double-edged sword in colorectal cancer progression.WNT5A:结直肠癌进展中的一把双刃剑
Mutat Res Rev Mutat Res. 2023 Jul-Dec;792:108465. doi: 10.1016/j.mrrev.2023.108465. Epub 2023 Jul 24.
3
Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer.
治疗性阻断 VEGF 与神经纤毛蛋白-2 的结合可降低 PD-L1 表达,激活前列腺癌中的抗肿瘤免疫。
Sci Transl Med. 2023 May 3;15(694):eade5855. doi: 10.1126/scitranslmed.ade5855.
4
Newly identified form of phenotypic plasticity of cancer: immunogenic mimicry.癌症表型可塑性的新形式:免疫模拟。
Cancer Metastasis Rev. 2023 Mar;42(1):323-334. doi: 10.1007/s10555-023-10087-1. Epub 2023 Feb 8.
5
WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth.WNT5a 通过 ROR2 信号激活 Hippo 通路,抑制 YAP1 活性并抑制肿瘤生长。
Cancer Res. 2023 Apr 4;83(7):1016-1030. doi: 10.1158/0008-5472.CAN-22-3003.
6
Interferon-dependent SLC14A1 cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer.干扰素依赖的 SLC14A1 癌症相关成纤维细胞通过 WNT5A 在膀胱癌中促进癌症干性。
Cancer Cell. 2022 Dec 12;40(12):1550-1565.e7. doi: 10.1016/j.ccell.2022.11.005. Epub 2022 Dec 1.
7
WNT5A drives interleukin-6-dependent epithelial-mesenchymal transition via the JAK/STAT pathway in keloid pathogenesis.在瘢痕疙瘩发病机制中,WNT5A通过JAK/STAT途径驱动白细胞介素-6依赖性上皮-间质转化。
Burns Trauma. 2022 Oct 7;10:tkac023. doi: 10.1093/burnst/tkac023. eCollection 2022.
8
HIF1α lactylation enhances KIAA1199 transcription to promote angiogenesis and vasculogenic mimicry in prostate cancer.低氧诱导因子1α乳酸化增强KIAA1199转录以促进前列腺癌中的血管生成和血管生成拟态。
Int J Biol Macromol. 2022 Dec 1;222(Pt B):2225-2243. doi: 10.1016/j.ijbiomac.2022.10.014. Epub 2022 Oct 6.
9
Modern paradigms for prostate cancer detection and management.前列腺癌检测与管理的现代模式。
Med J Aust. 2022 Oct 17;217(8):424-433. doi: 10.5694/mja2.51722. Epub 2022 Oct 2.
10
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).卡博替尼联合阿替利珠单抗治疗转移性去势抵抗性前列腺癌患者:多中心、开放标签、Ib 期试验(COSMIC-021)扩展队列的结果。
Lancet Oncol. 2022 Jul;23(7):899-909. doi: 10.1016/S1470-2045(22)00278-9. Epub 2022 Jun 9.